Addition of Multimodal Therapy to Standard Management of Steady State Sickle Cell Disease

Table 1

Number of sickle cell crises and steady state full blood count in HbSS patients before and 12 months after addition of potassium thiocyanate and omega-3 fatty acids to standard management with folic acid and paludrine.

Study identity number	Age (yrs) and gender	Crisis/year		Hb (g/dL)		WBC × 10^9/L		Platelets × 10^9/L
		Pre-Rx	Post-Rx	Pre-Rx	Post-Rx	Pre-Rx	Post-Rx	Pre-Rx	Post-Rx
1	23 F	6	3	9.3	9.8	14.5	7.2	392	210
2	33 M	15	4	8.3	9.8	11.8	8	315	285
3	19 M	4	2	10	9.1	10	9	100	209
4	26 F	5	2	7.6	8.8	8	9.1	226	240
5	11 M	7	2	6.6	6	9.2	5.6	233	430
6	8 M	3	1	8.9	10	11.6	4.9	197	185
7	14 M	5	1	7.5	8.6	23.8	9.6	495	270
8	9 M	3	1	7.7	7	15	14	373	350
9	5 F	6	1	8	6.7	19.4	11.5	170	195
10	6 M	3	0	8.6	6.5	19.1	6.1	84	130
11	16 M	3	1	8.3	7.6	11.2	20.8	470	358
12	16 M	3	5	7	7	6.4	5.9	240	325
13	18 F	3	0	10	8.1	5.9	10.6	253	263
14	17 M	3	1	7	4.9	17.3	10.3	160	Not done
15	18 F	3	2	6.3	7.4	6.2	10.9	505	350
16	3 M	3	0	7.5	8.3	23.5	17.5	303	388
Median		3	1	7.8	7.8	11.7	9.3	253	270
^∗𝑃 value		<0.0001		0.7		0.08		0.9

F: female; M: male; Pre-Rx: pretreatment; Post-Rx: posttreatment; *Mann-Whitney 𝑈 test, 2-tailed; pretreatment compared with posttreatment data.